Found: 24
Select item for more details and to access through your institution.
Case report and summary of literature: giant perineal keloids treated with post-excisional radiotherapy.
- Published in:
- BMC Dermatology, 2006, v. 6, p. 7, doi. 10.1186/1471-5945-6-7
- By:
- Publication type:
- Article
Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors.
- Published in:
- Investigational New Drugs, 2023, v. 41, n. 3, p. 380, doi. 10.1007/s10637-022-01326-3
- By:
- Publication type:
- Article
First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 3, p. 586, doi. 10.1007/s10637-022-01217-7
- By:
- Publication type:
- Article
A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 5, p. 1483, doi. 10.1007/s10637-020-00908-3
- By:
- Publication type:
- Article
A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody–drug conjugate, in patients with breast cancer and other advanced solid tumors.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 1, p. 120, doi. 10.1007/s10637-019-00754-y
- By:
- Publication type:
- Article
Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 4, p. 629, doi. 10.1007/s10637-017-0532-2
- By:
- Publication type:
- Article
PI-13.
- Published in:
- Clinical Pharmacology & Therapeutics, 2006, v. 79, n. 2, p. P10, doi. 10.1016/j.clpt.2005.12.034
- By:
- Publication type:
- Article
A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours.
- Published in:
- 2017
- By:
- Publication type:
- journal article
A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors.
- Published in:
- 2020
- By:
- Publication type:
- journal article
A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α<sub>5</sub>β<sub>1</sub> integrin monoclonal antibody (volociximab) in cancer patients.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2010, v. 65, n. 2, p. 207, doi. 10.1007/s00280-009-1023-8
- By:
- Publication type:
- Article
Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2009, v. 65, n. 1, p. 167, doi. 10.1007/s00280-009-1020-y
- By:
- Publication type:
- Article
Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2009, v. 63, n. 6, p. 1065, doi. 10.1007/s00280-008-0811-x
- By:
- Publication type:
- Article
Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2008, v. 62, n. 5, p. 911, doi. 10.1007/s00280-007-0672-8
- By:
- Publication type:
- Article
Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2008, v. 62, n. 1, p. 97, doi. 10.1007/s00280-007-0579-4
- By:
- Publication type:
- Article
A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2007, v. 59, n. 2, p. 165, doi. 10.1007/s00280-006-0255-0
- By:
- Publication type:
- Article
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.
- Published in:
- Journal of Hematology & Oncology, 2014, v. 7, n. 1, p. 3, doi. 10.1186/1756-8722-7-1
- By:
- Publication type:
- Article
Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.
- Published in:
- 2018
- By:
- Publication type:
- journal article
A Randomized Phase 2 Trial Comparing 3-Hour Versus 96-Hour Infusion Schedules of Paclitaxel for the Treatment of Metastatic Breast Cancer.
- Published in:
- Cancer (0008543X), 2010, v. 116, n. 4, p. 814, doi. 10.1002/cncr.24870
- By:
- Publication type:
- Article
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules.
- Published in:
- 2003
- By:
- Publication type:
- journal article